P&T Archived Drug Classes Motion

Drug Classes	Motion	Date Reviewed	Decision
Anticoagulant Antiplatelet Statins PCSK9 inhibitors	After considering the archive reports presented today, I move to archive the following drug classes from further regular review by the P&T Committee: Anticoagulant 02/28/2024* Antiplatelet 02/28/2024* Statins 02/28/2024* PCSK9 inhibitors 02/28/2024* *(date = last motion) The drug classes will remain on the PDL, and the committee's last motion will remain in effect until changed by the committee. The agencies may conduct updated cost analyses of these drug classes without additional committee approval so long as any resulting changes in the preferred status of a drug remains consistent with the committee's last motion for that drug class. The committee may review the archive status of a drug class upon its own initiative or by request of the participating agencies at any time. Motion: Flynn 2nd: Beste	2/28/2024	Passed unanimous